PT3774817T - Inibidores de bcl6 - Google Patents
Inibidores de bcl6Info
- Publication number
- PT3774817T PT3774817T PT197188345T PT19718834T PT3774817T PT 3774817 T PT3774817 T PT 3774817T PT 197188345 T PT197188345 T PT 197188345T PT 19718834 T PT19718834 T PT 19718834T PT 3774817 T PT3774817 T PT 3774817T
- Authority
- PT
- Portugal
- Prior art keywords
- bcl6 inhibitors
- bcl6
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1806132.5A GB201806132D0 (en) | 2018-04-13 | 2018-04-13 | Inhibitor coumpounds |
| GBGB1819136.1A GB201819136D0 (en) | 2018-11-23 | 2018-11-23 | Inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3774817T true PT3774817T (pt) | 2023-03-09 |
Family
ID=66240166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT197188345T PT3774817T (pt) | 2018-04-13 | 2019-04-12 | Inibidores de bcl6 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11512095B2 (pt) |
| EP (2) | EP3774817B1 (pt) |
| JP (1) | JP7493454B2 (pt) |
| KR (1) | KR20200144109A (pt) |
| CN (1) | CN112334475A (pt) |
| AU (2) | AU2019253510B2 (pt) |
| BR (1) | BR112020020832A2 (pt) |
| CA (1) | CA3095371A1 (pt) |
| DK (1) | DK3774817T3 (pt) |
| ES (1) | ES2939776T3 (pt) |
| HR (1) | HRP20230120T1 (pt) |
| IL (2) | IL296734A (pt) |
| MX (2) | MX2020010805A (pt) |
| PT (1) | PT3774817T (pt) |
| SG (1) | SG11202009735QA (pt) |
| WO (1) | WO2019197842A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3774817T (pt) * | 2018-04-13 | 2023-03-09 | The Institute Of Cancer Res Royal Cancer Hospital | Inibidores de bcl6 |
| GB201909573D0 (en) | 2019-07-03 | 2019-08-14 | Cancer Research Tech Ltd | Modulation of T cell cytotoxicity and related therapy |
| GB201914860D0 (en) * | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
| US20220323457A1 (en) * | 2019-10-17 | 2022-10-13 | Arvinas Operations, Inc. | Modulators of bcl6 proteolysis and associated methods of use |
| CN117279910A (zh) | 2021-04-16 | 2023-12-22 | 阿尔维纳斯运营股份有限公司 | Bcl6蛋白水解的调节剂和其相关使用方法 |
| WO2023240038A1 (en) | 2022-06-06 | 2023-12-14 | Treeline Biosciences, Inc. | Tricyclic quinolone bcl6 bifunctional degraders |
| WO2023244917A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders |
| WO2023244918A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
| WO2024019995A1 (en) * | 2022-07-19 | 2024-01-25 | Dana-Farber Cancer Institute, Inc. | Quinoxalinedione and pyrido [2, 3-b]pyrazine-2, 3-dione b cell lymphoma 6 (bcl6) degraders and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab | 4-anilinochinazolin derivate |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| DK1553097T3 (da) | 1999-02-10 | 2010-12-13 | Astrazeneca Ab | Quinazolinderivat som angiogeneseinhibitor og mellemprodukter dertil |
| IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| WO2002004434A1 (en) | 2000-07-07 | 2002-01-17 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as vascular damaging agents |
| MXPA02012903A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como inhibidores de angiogenesis. |
| MY140679A (en) | 2001-05-24 | 2010-01-15 | Avanir Pharmaceuticals | Inhibitors of macrohage migration inhibitory factor and methods for identifying the same |
| MX2011004957A (es) * | 2008-11-11 | 2011-08-12 | Je Il Pharmaceutical Co Ltd | Nuevo derivado triciclico o las sales farmaceuticamente aceptables del mismo, metodo de preparacion del mismo, y composicion farmaceutica que contiene el mismo. |
| MX2015010983A (es) | 2013-03-05 | 2015-10-26 | Hoffmann La Roche | Inhibidores de tirosina-cinasa de bruton. |
| WO2014204859A2 (en) | 2013-06-17 | 2014-12-24 | Melnick Ari | Bcl6 inhibitors as anticancer agents |
| WO2018108704A1 (en) | 2016-12-13 | 2018-06-21 | Boehringer Ingelheim International Gmbh | New 6-amino-quinolinone compounds and derivatives as bcl6 inhibitors |
| EP4371562A2 (en) * | 2017-05-26 | 2024-05-22 | Cancer Research Technology Limited | 2-quinolone derived inhibitors of bcl6 |
| KR102628675B1 (ko) | 2017-05-26 | 2024-01-25 | 캔써 리서치 테크놀로지 리미티드 | 벤즈이미다졸론 유래된 bcl6의 저해제 |
| PT3774817T (pt) * | 2018-04-13 | 2023-03-09 | The Institute Of Cancer Res Royal Cancer Hospital | Inibidores de bcl6 |
-
2019
- 2019-04-12 PT PT197188345T patent/PT3774817T/pt unknown
- 2019-04-12 IL IL296734A patent/IL296734A/en unknown
- 2019-04-12 HR HRP20230120TT patent/HRP20230120T1/hr unknown
- 2019-04-12 WO PCT/GB2019/051058 patent/WO2019197842A1/en active Application Filing
- 2019-04-12 CN CN201980039513.4A patent/CN112334475A/zh active Pending
- 2019-04-12 MX MX2020010805A patent/MX2020010805A/es unknown
- 2019-04-12 CA CA3095371A patent/CA3095371A1/en active Pending
- 2019-04-12 DK DK19718834.5T patent/DK3774817T3/da active
- 2019-04-12 SG SG11202009735QA patent/SG11202009735QA/en unknown
- 2019-04-12 US US17/046,650 patent/US11512095B2/en active Active
- 2019-04-12 KR KR1020207032149A patent/KR20200144109A/ko not_active Application Discontinuation
- 2019-04-12 JP JP2020555420A patent/JP7493454B2/ja active Active
- 2019-04-12 AU AU2019253510A patent/AU2019253510B2/en active Active
- 2019-04-12 EP EP19718834.5A patent/EP3774817B1/en active Active
- 2019-04-12 EP EP22211485.2A patent/EP4201939A1/en active Pending
- 2019-04-12 ES ES19718834T patent/ES2939776T3/es active Active
- 2019-04-12 BR BR112020020832-9A patent/BR112020020832A2/pt unknown
-
2020
- 2020-10-04 IL IL277778A patent/IL277778B2/en unknown
- 2020-10-12 MX MX2023004920A patent/MX2023004920A/es unknown
-
2022
- 2022-10-18 US US17/968,159 patent/US20230287003A1/en active Pending
-
2023
- 2023-11-09 AU AU2023263501A patent/AU2023263501A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11512095B2 (en) | 2022-11-29 |
| MX2023004920A (es) | 2023-05-16 |
| MX2020010805A (es) | 2021-01-29 |
| AU2019253510A1 (en) | 2020-10-22 |
| EP3774817A1 (en) | 2021-02-17 |
| WO2019197842A1 (en) | 2019-10-17 |
| IL296734A (en) | 2022-11-01 |
| CN112334475A (zh) | 2021-02-05 |
| ES2939776T3 (es) | 2023-04-26 |
| DK3774817T3 (da) | 2023-02-13 |
| US20210163497A1 (en) | 2021-06-03 |
| HRP20230120T1 (hr) | 2023-06-09 |
| IL277778B (en) | 2022-11-01 |
| AU2019253510B2 (en) | 2023-08-10 |
| SG11202009735QA (en) | 2020-10-29 |
| JP2021521165A (ja) | 2021-08-26 |
| IL277778A (en) | 2020-11-30 |
| US20230287003A1 (en) | 2023-09-14 |
| AU2023263501A1 (en) | 2023-11-30 |
| JP7493454B2 (ja) | 2024-05-31 |
| BR112020020832A2 (pt) | 2021-01-19 |
| EP3774817B1 (en) | 2022-12-07 |
| CA3095371A1 (en) | 2019-10-17 |
| EP4201939A1 (en) | 2023-06-28 |
| IL277778B2 (en) | 2023-03-01 |
| KR20200144109A (ko) | 2020-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283639A (en) | kif18a inhibitors | |
| IL292642A (en) | ras inhibitors | |
| IL292643A (en) | ras inhibitors | |
| IL292644A (en) | ras inhibitors | |
| SG11202009933WA (en) | Bcl-2 INHIBITORS | |
| IL269196A (en) | New inhibitors | |
| IL277778A (en) | BCL6 inhibitors | |
| IL276813A (en) | Arginase inhibitors | |
| ZA201907136B (en) | Ip6k inhibitors | |
| EP3817736A4 (en) | PIKFYVE INHIBITORS | |
| GB201819126D0 (en) | Inhibitor compounds | |
| IL276013A (en) | pi4kiiibeta inhibitors | |
| ZA201808552B (en) | Novel b-lactamase inhibitors | |
| EP3600301A4 (en) | KDM4 INHIBITORS | |
| IL283309A (en) | rip1 inhibitors | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | |
| IL277806A (en) | Growth inhibitor | |
| IL274550A (en) | Dopamine-B-hydroxylase inhibitors | |
| IL283112A (en) | Lox inhibitors | |
| GB201809295D0 (en) | Lox inhibitors | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors | |
| GB201812462D0 (en) | Inhibitors | |
| GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors | |
| GB201809939D0 (en) | Eastase inhibitor |